Stockscreener 앱 받기
35.69
1.16%
0.41
시장 영업 전:
35.00
-0.69
-1.93%
전일 마감가:
$35.28
열려 있는:
$35.28
하루 거래량:
1.08M
Relative Volume:
0.52
시가총액:
$3.80B
수익:
$741.17M
순이익/손실:
$104.65M
주가수익비율:
40.78
EPS:
0.8752
순현금흐름:
$162.57M
1주 성능:
-1.46%
1개월 성능:
-11.06%
6개월 성능:
-48.55%
1년 성능:
-36.26%
1일 변동 폭
$34.93
$36.05
1주일 범위
$33.99
$36.47
52주 변동 폭
$28.66
$117.33
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
35.69 | 3.75B | 741.17M | 104.65M | 162.57M | 0.8752 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-31 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 개시 | UBS | Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics IncorporatedCORT - ChartMill
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Corcept Therapeutics (NASDAQ: CORT) Form 144 lists 20,000-share sale on 03/04/2026 - Stock Titan
CORT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Law Offices of Frank R. Cruz Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action - wjfw.com
Lost Money on Corcept Therapeutics Incorporated(CORT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - PR Newswire
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS) - Seeking Alpha
Corcept Therapeutics faces securities lawsuit over FDA rejection By Investing.com - Investing.com Canada
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - GlobeNewswire Inc.
[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity - Stock Titan
Corcept (CORT) CEO awarded 460,000 stock options in new grant - Stock Titan
Corcept Therapeutics (CORT) officer awarded stock options on 140,000 shares - Stock Titan
Corcept Therapeutics (CORT) CFO awarded stock options on 140,000 shares - Stock Titan
Corcept Therapeutics (CORT) CSO Hazel Hunt awarded 140,000 stock options - Stock Titan
Corcept (NASDAQ: CORT) grants CBO 140,000 options vesting over four years - Stock Titan
Investors of Corcept Therapeutics, Inc. (CORT) Seeking Recovery - The National Law Review
CORCEPT THERAPEUTICS INCORPORATED (CORT) DEADLINE ALERT Bernstein Liebhard LLP Reminds Corcept Therapeutics Incorporated Investors of Upcoming Deadline - ACCESS Newswire
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); ... - Bluefield Daily Telegraph
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Integer Holdings Corp. (NYSE: ITGR); Kyndryl Holdings (NYSE: KD); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your Beha - GlobeNewswire
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Integer Holdings Corp. (NYSE: ITGR); Kyndryl Holdings (NYSE: KD); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Corcept - GlobeNewswire
Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline - ChartMill
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Corcept Therapeutics Incorporated LawsuitCORT - PR Newswire
CORT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit - Financial Times
ARDT IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Ardent Health, Inc. Investors to Secure Counsel Before Important March 9 Deadline in Securities Class Action - GlobeNewswire Inc.
Shareholders who lost money in shares of Corcept - GlobeNewswire
ROSEN, A LEADING AND RANKED FIRM, Encourages Corcept - GlobeNewswire
FinancialContentDeadline to Lead in Securities Class Action Against Corcept Therapeutics, Inc. (CORT) is April 21, 2026Contact Kaplan Fox - FinancialContent
Deadline Approaching: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith - FinancialContent
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Five9, ... - Bluefield Daily Telegraph
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Five9, Inc. (NASDAQ - marketscreener.com
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Average Recommendation of "Hold" by Analysts - MarketBeat
How Relacorilant Setback and Lawsuits Will Impact Corcept Therapeutics’ (CORT) Risk-Reward Profile - simplywall.st
Corcept Therapeutics Accused of Misleading Investors in Class Action - Intellectia AI
Corcept Therapeutics (CORT) Litigation: Hagens Berman - GlobeNewswire
Canaccord Genuity Keeps Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail
Corcept Therapeutics Lawsuits And CRL Put Relacorilant Story Under Pressure - Yahoo Finance
What is Corcept Therapeutics Incorporated’s market positionJuly 2025 Summary & Safe Entry Point Identification - mfd.ru
CORCEPT THERAPEUTICS INCORPORATED (CORT) Stock, Price, News, Quotes, Forecast and Insights - MSN
Is Corcept Therapeutics (CORT) Pricing Reflect Its Sharp One Year Share Price Decline - Yahoo Finance
HC Wainwright Analysts Increase Earnings Estimates for CORT - MarketBeat
TD Asset Management Inc Grows Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
A Look At Corcept Therapeutics (CORT) Valuation After Relacorilant FDA Setback And New Lawsuits - simplywall.st
Corcept Therapeutics v. Teva Pharmaceuticals: Going Outside The Label To Show No Direct Infringement - Mondaq
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - mydailyrecord.com
Corcept (CORT) director exercises options and moves shares to family trusts - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming DeadlinesCORT - PR Newswire
Corcept Therapeutics (NASDAQ: CORT) Investors Who Have Suffered LossesContact Kaplan Fox before April 21, 2026 Lead Plaintiff Deadline - NewMediaWire
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):